PremiumThe FlyClosing Bell Movers: Levi Strauss down 10% on reduced FY24 revenue view Processa Pharmaceuticals jumps 28% after Phase 2 study update Processa: First patient dosed in Phase 2 clinical trial of NGC-Cap for MBC PremiumThe FlyProcessa Pharmaceuticals announces FDA clearance of IND application for NGC-Cap Processa Pharmaceuticals Welcomes New CFO Russell Skibsted Processa Pharmaceuticals appoints Skibsted as CFO PremiumThe FlyProcessa Pharmaceuticals initiated with a Buy at H.C. Wainwright Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial Processa Pharmaceuticals’ Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks 
